What are the current challenges in targeting Rho GTPases in Cancer therapy?
Despite the potential, several challenges exist: 1. Specificity: Achieving selective inhibition of specific Rho GTPases without affecting others. 2. Toxicity: Minimizing off-target effects and systemic toxicity. 3. Resistance: Understanding and overcoming resistance mechanisms that cancer cells might develop against Rho GTPase inhibitors. 4. Delivery: Effective delivery of inhibitors to tumor cells while avoiding normal cells.
